

PRESS RELEASE:

August 13, 2021  
Fuji Pharma Co., Ltd.

**Fuji Pharma and Lotus finalized co-development and license agreement  
for the 1<sup>st</sup> high value generic product in Japan**

Fuji Pharma Co., Ltd. ("Fuji") announced today that Fuji has finalized co-development arrangements and entered into an exclusive license agreement with Lotus Pharmaceutical Co., Ltd. (Head Office: Taiwan, TPEX ticker:1795, "Lotus") for developing and distributing 1<sup>st</sup> high value generic drug product in Japan.

Fuji and Lotus have entered into a capitalization and business alliance agreement with the aim of introducing Lotus's pipeline in Japan, as described in "Lotus and Fuji Confirm Cross-Investment Partnership to Further Strengthen Their Positions in Asia" on March 20, 2019. The conclusion of this agreement will further strengthen Fuji's domestic product line-up.

Fuji and Lotus will continue to discuss expanding our lineup of products based on the capital-and-business alliance of the partner. Fuji will continue our efforts to expand our product lineup and make further contributions in the healthcare field and the healthcare economy.

**[About Lotus]**

Lotus is an Alvogen Company with high-value, complex generic products specializing in oncology, CNS, CVS, women health, and anti-obesity drugs. Headquartered in Taiwan, Lotus has been building commercial platforms across APAC since Alvogen's majority investment in 2014 and successfully transformed to be Alvogen's regional hub in Asian markets. In addition to its current direct markets in Taiwan and Korea, Lotus is also developing SEA markets, including Thailand and Vietnam, by consolidating Alvogen's local infrastructure to offer more resourceful services on a well-established platform in all countries across the region. By aligning the Company's internal best-in-class development and manufacturing capabilities, Lotus aims to benefit patients, its employees and shareholders alike.

**For further information, contact**

Fuji Pharma Co., Ltd.

Corporate Communication Section, Corporate Planning Department,

[fsk\\_ir@fujipharma.jp](mailto:fsk_ir@fujipharma.jp)